Dyrk1a from gene function in development and physiology to dosage correction across life span in down syndrome

Anorexigenic and Orexigenic Hormone Modulation of Mammalian Target of Rapamycin Complex 1 Activity and the Regulation of Hypothalamic Agouti-Related Protein mRNA Expression

Watterson, K. R., Bestow, D., Gallagher, J. R., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2012) · Neurosignals · doi:10.1159/000334144 · Cited by 3,395 · see citing works

Biochemical Pathways of Caspase Activation During Apoptosis

Budihardjo, I. I., Oliver, H., Lutter, M. L., Luo, X., & Wang, X. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.269 · Cited by 2,562 · see citing works

The selectivity of protein kinase inhibitors: a further update

Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I. V., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,522 · see citing works

The specificities of protein kinase inhibitors: an update

BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1× · see citing works

A mouse model for Down syndrome exhibits learning and behaviour deficits

Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · see citing works

NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21

Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698 · see citing works

α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease

Chen, L., & Feany, M. Β. (2005) · Nature Neuroscience · doi:10.1038/nn1443 · Cited by 614 · see citing works

Modulation of mammalian life span by the short isoform of p53

Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586 · see citing works

The Synaptic Function of α-Synuclein

Burré, J. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150642 · Cited by 579 · see citing works

A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome

Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562 · see citing works

Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK

Allan, L. A., MORRICE, N. A., Brady, S. C., Magee, G. J., Pathak, S., & Clarke, P. R. (2003) · Nature Cell Biology · doi:10.1038/ncb1005 · Cited by 474 · see citing works

Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome

Kleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459 · see citing works

A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT

Gwack, Y., Sharma, S., Nardone, J., Tanasă, B., Iuga, A. C., Srikanth, S., Okamura, H., Bolton, D. L., Feske, S., Hogan, P. G., et al. (2006) · Nature · doi:10.1038/nature04631 · Cited by 397 · see citing works

Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome

Altafaj, X. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1915 · Cited by 396 · see citing works

Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities

Sago, H., Carlson, E. J., Smith, D. J., Kilbridge, J., Rubin, E. M., Mobley, W. C., Epstein, C. J., & Huang, T.-T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6256 · Cited by 382 · see citing works

minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila

Tejedor, F. J., Zhu, X., Kaltenbach, E., Ackermann, A., Baumann, A., Canal, I., Heisenberg, M., Fischbach, K. F., & Pongs, O. (1995) · Neuron · doi:10.1016/0896-6273(95)90286-4 · Cited by 379 · see citing works

Memory formation depends on both synapse-specific modifications of synaptic strength and cell-specific increases in excitability

Lisman, J., Cooper, K., Sehgal, M., & Silva, A. J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0076-6 · Cited by 351 · see citing works

The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bɛ at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase

Woods, Y. L., Cohen, P., Becker, W. B., Jakes, R., Goedert, M., Wang, X., & Proud, C. G. (2001) · Biochemical Journal · doi:10.1042/bj3550609 · Cited by 343 · see citing works

Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice

Fotaki, V., Dierssen, M., Alcántara, S., Martı́nez, S., Martı́, E., Casas, C., Visa, J., Soriano, E., Estivill, X., & Arbonés, M. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6636-6647.2002 · Cited by 330 · see citing works

MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling

Martins, P. A. D. C., Salic, K., Gladka, M. M., Armand, A., Leptidis, S., el Azzouzi, H., Hansen, A., Roo, C. J. J. C., Bierhuizen, M. F. A., van der Nagel, R., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2126 · Cited by 324 · see citing works

Activation-Loop Autophosphorylation Is Mediated by a Novel Transitional Intermediate Form of DYRKs

Lochhead, P. A., Sibbet, G. J., MORRICE, N. A., & Cleghon, V. (2005) · Cell · doi:10.1016/j.cell.2005.03.034 · Cited by 323 · see citing works

DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly

Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P., & DeCaprio, J. A. (2011) · Genes & Development · doi:10.1101/gad.2034211 · Cited by 302 · see citing works

The Apoptosome Activates Caspase-9 by Dimerization

Pop, C., Timmer, J. C., Sperandio, S., & Salvesen, G. S. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.009 · Cited by 294 · see citing works

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial

de la Torre, R., de Sola, S., Hernández, G., Farré, M., Pujol, J., Rodríguez, J. C., Espadaler, J. M., Langohr, K., Cuenca‐Royo, A., Príncipe, A., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30034-5 · Cited by 291 · see citing works

The role of DYRK1A in neurodegenerative diseases

Węgiel, J., Gong, C., & Hwang, Y. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07955.x · Cited by 288 · see citing works

DYRK1A-mediated Hyperphosphorylation of Tau

Ryoo, S., Jeong, H. K., Radnaabazar, C., Yoo, J.-J., Cho, H.-J., Lee, H. W., Kim, I.-S., Cheon, Y. H., Ahn, Y. S., Chung, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707358200 · Cited by 285 · see citing works

Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases

Becker, W. B., Weber, Y. G., Wetzel, K., EIRMBTER, K., Tejedor, F. J., & Joost, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25893 · Cited by 285 · see citing works

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in D own syndrome mouse models and in humans

de la Torre, R., Sola, S. D., Pons‐Espinal, M., Duchon, A., de Lagrán, M. M., Farré, M., Fitó, M., Benejam, B., Langohr, K., Rodríguez, J. C., et al. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300325 · Cited by 283 · see citing works

Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with down syndrome and in Ts65Dn mice

Contestabile, A., Fila, T., Ceccarelli, C., Bonasoni, P., Bonapace, L., Santini, D., Bartesaghi, R., & Ciani, E. (2007) · Hippocampus · doi:10.1002/hipo.20308 · Cited by 281 · see citing works

The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease

Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281 · see citing works

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

Ogawa, Y., Nonaka, Y., Goto, T., Ohnishi, E., Hiramatsu, T., Kii, I., Yoshida, M., Ikura, T., Onogi, H., Shibuyà, H., et al. (2010) · Nature Communications · doi:10.1038/ncomms1090 · Cited by 276 · see citing works

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome

Liu, F., Liang, Z., Wegiel, J., Hwang, Y., Iqbal, K., Grundke‐Iqbal, I., Ramakrishna, N., & Gong, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-104539 · Cited by 272 · see citing works

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

Göckler, N., Jofré, G., Papadopoulos, C., Soppa, U., Tejedor, F., & Becker, W. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07346.x · Cited by 266 · see citing works

The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site

Woods, Y. L., Rena, G., MORRICE, N. A., Barthel, A., Becker, W. B., Guo, S., Unterman, T. G., & Cohen, P. (2001) · Biochemical Journal · doi:10.1042/bj3550597 · Cited by 265 · see citing works

Olig1 and Olig2 triplication causes developmental brain defects in down syndrome.

Chakrabarti, L., Best, T. K., Cramer, N. P., Carney, R. S. E., Isaac, J. T. R., Galdzicki, Z., & Haydar, T. F. (2010) · Nature Neuroscience · doi:10.1038/nn.2600 · Cited by 258 · see citing works

Inhibition of Monoamine Oxidase A by β-Carboline Derivatives

Kim, H., Sablin, S. O., & Ramsay, R. R. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9771 · Cited by 252 · see citing works

DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1

Guo, X., Williams, J. G., Schug, T. T., & Li, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102574 · Cited by 237 · see citing works

Specificity Determinants of Substrate Recognition by the Protein Kinase DYRK1A

Himpel, S., Tegge, W. J., Frank, R., Leder, S., Joost, H., & Becker, W. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2431 · Cited by 235 · see citing works

Loss of Cholinergic Phenotype in Basal Forebrain Coincides with Cognitive Decline in a Mouse Model of Down's Syndrome

Granholm, A., Sanders, L., & Crnic, L. S. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7289 · Cited by 229 · see citing works

Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease

Ryoo, S., Cho, H., Lee, H. W., Jeong, H. K., Radnaabazar, C., Kim, Y., Kim, M., Son, M., Seo, H., Chung, S., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05075.x · Cited by 227 · see citing works

Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling down syndrome

Duchon, A., Raveau, M., Chevalier, C., Nalesso, V., Sharp, A. J., & Herault, Y. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9356-0 · Cited by 224 · see citing works

The Protein Interaction Landscape of the Human CMGC Kinase Group

Varjosalo, M. T., Keskitalo, S., van Drogen, A., Nurkkala, H., Vichalkovski, A., Aebersold, R. H., & Gstaiger, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.027 · Cited by 221 · see citing works

Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities

Li, Z., Yu, T., Morishima, M., Pao, A., LaDuca, J., Conroy, J., Nowak, N., Matsui, S.-I., Shiraishi, I., & Yu, Y. E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm086 · Cited by 218 · see citing works

A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region

Guimerá, J. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.9.1305 · Cited by 217 · see citing works

Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A

Guedj, F., Sebrié, C., Rivals, I., Ledru, A., Paly, E., Bizot, J. C., Smith, D., Rubin, E. M., Gillet, B., Arbonés, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004606 · Cited by 216 · see citing works

MNB/DYRK1A as a multiple regulator of neuronal development

Tejedor, F. J., & Hämmerle, B. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07954.x · Cited by 214 · see citing works

Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A

Himpel, S., PANZER, P., EIRMBTER, K., Czajkowska, H., Sayed, M., Packman, L. C., Blundell, T. L., Kentrup, H., Grötzinger, J., Joost, H., et al. (2001) · Biochemical Journal · doi:10.1042/bj3590497 · Cited by 209 · see citing works

Function and regulation of Dyrk1A: towards understanding Down syndrome

Park, J., Song, W., & Chung, K. C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0123-2 · Cited by 205 · see citing works

Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID

van Bon, B. W. M., Coe, B. P., Bernier, R., Green, C., Gerdts, J., Witherspoon, K., Kleefstra, T., Willemsen, M. H., Kumar, R., Bosco, P., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.5 · Cited by 204 · see citing works

Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B

Tahtouh, T., Elkins, J. M., Filippakopoulos, P., Soundararajan, M., Burgy, G., Durieu, É., Cochet, C., Schmid, R. S., Lo, D. C., Delhommel, F., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301034u · Cited by 203 · see citing works

Inhibition of DYRK1A and GSK3B induces human β-cell proliferation

Shen, W., Taylor, B. L., Jin, Q., Nguyen-Tran, V. T. B., Meeusen, S., Zhang, Y.-Q., Kamireddy, A., Swafford, A. D.-E., Powers, A. F., Walker, J. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9372 · Cited by 203 · see citing works

Down's dyndrome and Alzheimer's disease: dendritic spine counts in the hippocampus

Ferrer, I., & Gullotta, F. (1990) · Acta Neuropathologica · doi:10.1007/bf00294247 · Cited by 201 · see citing works

Loss of Ras activity in Saccharomyces cerevisiae is suppressed by disruptions of a new kinase gene, YAKI, whose product may act downstream of the cAMP-dependent protein kinase.Preprint

Garrett, S., & Broach, J. R. (1989) · Genes & Development · doi:10.1101/gad.3.9.1336 · Cited by 200 · see citing works

Rodent models in Down syndrome research: impact and future opportunities

Hérault, Y., Delabar, J. M., Fisher, E., Tybulewicz, V. L. J., Yu, E. Y., & Brault, V. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029728 · Cited by 191 · see citing works

Regulation of Gli1 Transcriptional Activity in the Nucleus by Dyrk1

Mao, J., Maye, P. F., Kogerman, P., Tejedor, F. J., Toftgård, R., Xie, W., Wu, G., & Wu, D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206743200 · Cited by 190 · see citing works

Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome: A quantitative golgi study

Suetsugu, M., & Mehraein, P. (1980) · Acta Neuropathologica · doi:10.1007/bf00688755 · Cited by 190 · see citing works

The Down syndrome-related protein kinase DYRK1A phosphorylates p27^Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation

Soppa, U., Schumacher, J., Florencio Ortiz, V., Pasqualon, T., Tejedor, F., & Becker, W. (2014) · Cell Cycle · doi:10.4161/cc.29104 · Cited by 189 · cited 4× · see citing works

HumanMinibrainHomologue (MNBH/DYRK1): Characterization, Alternative Splicing, Differential Tissue Expression, and Overexpression in Down Syndrome

Guimera, J., Casas, C., Estivill, X., & Pritchard, M. (1999) · Genomics · doi:10.1006/geno.1999.5775 · Cited by 186 · see citing works

Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome

Siarey, R. J., Carlson, E. J., Epstein, C. J., Balbo, A., Rapoport, S. I., & Galdzicki, Z. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00083-0 · Cited by 184 · see citing works

Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models

Ferrer, I., Barrachina, M., Puig, B., de Lagrán, M. M., Martı́, E., Ávila, J., & Dierssen, M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.020 · Cited by 181 · see citing works

DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome

Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181 · see citing works

Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome

Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Węgiel, J., Zhou, J., Hwang, Y., Iqbal, K., Grundke, I., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802645200 · Cited by 179 · see citing works

Pom1 DYRK Regulates Localization of the Rga4 GAP to Ensure Bipolar Activation of Cdc42 in Fission Yeast

Tatebe, H., Nakano, K., Maximo, R., & Shiozaki, K. (2008) · Current Biology · doi:10.1016/j.cub.2008.02.005 · Cited by 178 · see citing works

β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites

Frost, D., Meechoovet, B., Wang, T., Gately, S. T., Giorgetti, M., Shcherbakova, I. M., & Dunckley, T. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019264 · Cited by 177 · see citing works

Structural Basis for the Non-catalytic Functions of Protein Kinases

Kung, J. E., & Jura, N. (2016) · Structure · doi:10.1016/j.str.2015.10.020 · Cited by 176 · see citing works

Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells

Yang, E. J., Ahn, Y. S., & Chung, K. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104091200 · Cited by 172 · see citing works

Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly

Møller, R. S., Kübart, S., Hoeltzenbein, M., Heye, B., Vogel, I., Hansen, C. P., Menzel, C., Ullmann, R., Tommerup, N., Ropers, H.-H., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.03.001 · Cited by 163 · see citing works

Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing

Debdab, M., Carreaux, F., Renault, S., Soundararajan, M., Fedorov, O., Filippakopoulos, P., Lozach, O., Babault, L., Tahtouh, T., Baratte, B., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200274d · Cited by 162 · see citing works

DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly

Álvarez‐Fernández, M., Estivill, X., & de la Luna, S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00618 · Cited by 161 · see citing works

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition

Soundararajan, M., Roos, A. K., Savitsky, P. A., Filippakopoulos, P., Kettenbach, A. N., Olsen, J. V., Gerber, S. A., Eswaran, J., Knapp, S., & Elkins, J. M. (2013) · Structure · doi:10.1016/j.str.2013.03.012 · Cited by 160 · see citing works

DYRK1A: A master regulatory protein controlling brain growth

Guedj, F., Pereira, P. L., Najas, S., Barallobre, M. J., Chabert, C., Souchet, B., Sebrié, C., Verney, C., Hérault, Y., Arbonés, M. L., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.007 · Cited by 155 · see citing works

Dyrk1A Overexpression Inhibits Proliferation and Induces Premature Neuronal Differentiation of Neural Progenitor Cells

Yabut, O., Domogauer, J., & D’Arcangelo, G. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4711-09.2010 · Cited by 154 · see citing works

Reducing GABA A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome

Martínez‐Cué, C., Martinez, P. M., Rueda, N., Vidal, R., García-Cerro, S., Vidal, V., Corrales, A., Montero, J. A., Pazos, Á., Flórez, J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1203-12.2013 · Cited by 154 · see citing works

p53 downregulates Down syndrome‐associated DYRK1A through miR‐1246

Zhang, Y., Liao, J., Zeng, S. X., & Lu, H. (2011) · EMBO Reports · doi:10.1038/embor.2011.98 · Cited by 146 · see citing works

Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle

Chen, J.-Y., Lin, J.-R., Tsai, F.-C., & Meyer, T. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.09.009 · Cited by 144 · see citing works

The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome

Contestabile, A., Magara, S., & Cancedda, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00054 · Cited by 141 · see citing works

DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome

Lepagnol-Bestel, A.-M., Zvara, Á., Maussion, G., Quignon, F., Ngimbous, B., Ramoz, N., Imbeaud, S., Loe-Mie, Y., Benihoud, K., Agier, N., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp047 · Cited by 137 · see citing works

Transient expression of <i>Mnb/Dyrk1a</i> couples cell cycle exit and differentiation of neuronal precursors by inducing <i>p27KIP1</i> expression and suppressing NOTCH signaling

Hämmerle, B., Ulin, E., Guimera, J., Becker, W., Guillemot, F., & Tejedor, F. J. (2011) · Development · doi:10.1242/dev.066167 · Cited by 137 · see citing works

Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system

Martı́, E., Altafaj, X., Dierssen, M., de la Luna, S., Fotaki, V., Alvarez, M., Pérez-Riba, M., Ferrer, I., & Estivill, X. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04069-6 · Cited by 136 · see citing works

Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells

Park, J., Oh, Y., Yoo, L., Jung, M.-S., Song, W.-J., Lee, S.-H., Seo, H., & Chung, K. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147520 · Cited by 134 · see citing works

DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine

Seifert, A., Allan, L. A., & Clarke, P. R. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06751.x · Cited by 132 · see citing works

The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.

Laguna, A., Aranda, S., Barallobre, M., Barhoum, R., Fernández, E., Fotaki, V., Delabar, J., de la Luna, S., de la Villa, P., & Arbonés, M. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.10.014 · Cited by 131 · see citing works

Chromatin-wide Profiling of DYRK1A Reveals a Role as a Gene-Specific RNA Polymerase II CTD Kinase

Vona, C. D., Bezdan, D., Islam, A. B. M. M. K., Salichs, E., López-Bigas, N., Ossowski, S., & de la Luna, S. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.026 · Cited by 129 · see citing works

A kinase shRNA screen links LATS2 and the pRB tumor suppressorPreprint

Tschöp, K., Conery, A. R., Litovchick, L., DeCaprio, J. A., Settleman, J. E., Harlow, E., & Dyson, N. J. (2011) · Genes & Development · doi:10.1101/gad.2000211 · Cited by 125 · see citing works

Characterization of Cyclin L2, a Novel Cyclin with an Arginine/Serine-rich Domain

de Graaf, K., Hekerman, P., Spelten, O., Herrmann, A., Packman, L. C., Büssow, K., Müller-Newen, G., & Becker, W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310794200 · Cited by 124 · see citing works

The <i>DYRK1A</i> gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy

Courcet, J.-B., Faivre, L., Malzac, P., Masurel-Paulet, A., Lopez, E., Callier, P., Lambert, L., Lemesle, M., Thevenon, J., Gigot, N., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101251 · Cited by 121 · see citing works

Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly

van Bon, B., Hoischen, A., Hehir-Kwa, J., de Brouwer, A., Ruivenkamp, C., Gijsbers, A., Marcelis, C., de Leeuw, N., Veltman, J., Brunner, H., et al. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01544.x · Cited by 117 · see citing works

A chemical with proven clinical safety restores Down syndrome-related phenotypes via DYRK1A inhibition

Kim, H., Lee, K., Kim, A., Choi, M., Choi, K., Kang, M.-G., Chi, S., Lee, M., Lee, J.-S., Lee, S., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025668 · Cited by 117 · see citing works

Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation

Kim, E. J., Sung, J. Y., Lee, H. J., Rhim, H., Hasegawa, M., Iwatsubo, T., Min, D. S., Kim, J., Paik, S. R., & Chung, K. C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606147200 · Cited by 113 · see citing works

Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage

Souchet, B., Guedj, F., Sahún, I., Duchon, A., Daubigney, F., Badel, A., Yanagawa, Y., Barallobre, M. J., Dierssen, M., Yu, E. Y., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.016 · Cited by 112 · see citing works

Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice

Seo, H., & Ole Isacson, A. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.017 · Cited by 112 · see citing works

Dyrk1A‐mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer’s disease

Ryu, Y. S., Park, S. Y., Jung, M., Yoon, S., Kwen, M., Lee, S., Choi, S. H., Radnaabazar, C., Kim, M., Kim, H., et al. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06769.x · Cited by 111 · see citing works

Phosphorylation of Ser640 in Muscle Glycogen Synthase by DYRK Family Protein Kinases

Skurat, A. V., & Dietrich, A. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m301769200 · Cited by 110 · see citing works

10-Iodo-11 H -indolo[3,2- c ]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A

Falke, H., Chaikuad, A., Becker, A., Loaëc, N., Lozach, O., Jhaisha, S. A., Becker, W. B., Jones, P. G., Preu, L., Baumann, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501994d · Cited by 109 · see citing works

The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site

de Graaf, K., Czajkowska, H., Rottmann, S., Packman, L. C., Lilischkis, R., Lüscher, B., & Becker, W. B. (2006) · BMC Biochemistry · doi:10.1186/1471-2091-7-7 · Cited by 109 · see citing works

RhoA Regulates Dendrite Branching in Hippocampal Neurons by Decreasing Cypin Protein Levels

Chen, H., & Firestein, B. L. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0872-07.2007 · Cited by 107 · see citing works

Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate

Chen-Hwang, M.-C., Chen, H.-R., Elzinga, M., & Hwang, Y.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111101200 · Cited by 106 · see citing works

Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control

Becker, W. B. (2012) · Cell Cycle · doi:10.4161/cc.21404 · Cited by 104 · see citing works

Phosphorylation of β-Tubulin by the Down Syndrome Kinase, Minibrain/DYRK1a, Regulates Microtubule Dynamics and Dendrite Morphogenesis

Ori-McKenney, K. M., McKenney, R. J., Huang, H. H., Li, T., Meltzer, S., Jan, L. Y., Vale, R. D., Wiita, A. P., & Jan, Y. N. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.027 · Cited by 104 · see citing works

Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation

Hämmerle, B., Carnicero, A., Elizalde, C., Cerón, J., Martı́nez, S., & Tejedor, F. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02665.x · Cited by 103 · see citing works

Construction of a Panel of Transgenic Mice Containing a Contiguous 2-Mb Set of YAC/P1 Clones from Human Chromosome 21q22.2

Smith, D., Zhu, Y., Zhang, J., Cheng, J., & Rubin, E. M. (1995) · Genomics · doi:10.1006/geno.1995.1073 · Cited by 102 · see citing works

Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome

Dierssen, M., Vallina, I. F., Baamonde, C., Calatayud, S. G., Lumbreras, M., & Flórez, J. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01173-0 · Cited by 101 · see citing works

Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A

Wu, Q., Liang, H., Shi, J., Jin, N., Grundke, I., Iqbal, K., Gong, C., & Liu, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr195 · Cited by 100 · see citing works

Normalizing the gene dosage of Dyrk1A in a mouse model of down syndrome rescues several Alzheimer’s disease phenotypes

García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100 · see citing works

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98 · see citing works

Protein Kinase A Regulates Caspase-9 Activation by Apaf-1 Downstream of Cytochrome c

Martin, M. C., Allan, L. A., Lickrish, M., Sampson, C., MORRICE, N. A., & Clarke, P. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414325200 · Cited by 97 · see citing works

Small-Molecule Inducer of β Cell Proliferation Identified by High-Throughput Screening

Shen, W., Tremblay, M. S., Deshmukh, V. A., Wang, W., Filippi, C. M., Harb, G., Zhang, Y.-Q., Kamireddy, A., Baaten, J., Jin, Q., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja309304m · Cited by 97 · see citing works

Neural Activity Regulates Synaptic Properties and Dendritic Structure In Vivo through Calcineurin/NFAT Signaling

Schwartz, N., Schohl, A., & Ruthazer, E. S. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.007 · Cited by 94 · see citing works

Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion

Yin, X., Jin, N., Gu, J., Shi, J., Zhou, J., Gong, C., Iqbal, K., Grundke, I., & Liu, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355412 · Cited by 93 · see citing works

Prefrontal Deficits in a Murine Model Overexpressing the Down Syndrome Candidate GeneDyrk1a

Thomazeau, A., Lassalle, O., Iafrati, J., Souchet, B., Guedj, F., Janel, N., Chavis, P., Delabar, J. M., & Manzoni, O. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2852-13.2014 · Cited by 93 · see citing works

Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/− mouse

Benavides‐Piccione, R., Dierssen, M., Ballesteros‐Yáñez, I., de Lagrán, M. M., Arbonés, M. L., Fotaki, V., DeFelipe, J., & Elston, G. N. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.02.004 · Cited by 92 · see citing works

DYRK1A-mediated cyclin D1 degradation in neural stem cells contributes to the neurogenic cortical defects in down syndrome

Najas, S., Arranz, J., Lochhead, P. A., Ashford, A. L., Oxley, D., Delabar, J. M., Cook, S. J., Barallobre, M. J., & Arbonés, M. L. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.01.010 · Cited by 92 · see citing works

Dyrk1A Influences Neuronal Morphogenesis Through Regulation of Cytoskeletal Dynamics in Mammalian Cortical Neurons

de Lagrán, M. M., Benavides‐Piccione, R., Ballesteros‐Yáñez, I., Calvo, M., Morales, M., Fillat, C., DeFelipe, J., Ramakers, G. J. A., & Dierssen, M. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr362 · Cited by 90 · see citing works

Selective inhibition of the kinase DYRK1A by targeting its folding process

Kii, I., Sumida, Y., Goto, T., Sonamoto, R., Okuno, Y., Yoshida, S., Kato‐Sumida, T., Koike, Y., Abe, M., Nonaka, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11391 · Cited by 90 · see citing works

Regulation of RCAN1 Protein Activity by Dyrk1A Protein-mediated Phosphorylation

Jung, M., Park, J., Ryu, Y. S., Choi, S., Yoon, S., Kwen, M., Oh, J. Y., Song, W., & Chung, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.253971 · Cited by 89 · see citing works

DYRK1A autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding.

Álvarez, M., Altafaj, X., Aranda, S., & de la Luna, S. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-08-0668 · Cited by 88 · see citing works

Genetic dissection of the down syndrome critical region

Jiang, X., Liu, C., Yu, T., Zhang, L., Meng, K., Xing, Z., Belichenko, P. V., Kleschevnikov, A. M., Pao, A., Peresie, J., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv364 · Cited by 88 · see citing works

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

Nguyen, T. L., Duchon, A., Manousopoulou, A., Loaëc, N., Villiers, B., Pani, G., Karatas, M., Mechling, A. E., Harsan, L. A., Limanton, E., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035634 · Cited by 87 · see citing works

Reduced cell number in the neocortical part of the human fetal brain in Down syndrome

Larsen, K. B., Laursen, H., Græm, N., Samuelsen, G. B., Bogdanovic, N., & Pakkenberg, B. (2008) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2008.05.007 · Cited by 87 · see citing works

Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism

Vingtdeux, V., Hamdane, M., Gompel, M., Bégard, S., Drobecq, H., Ghestem, A., Grosjean, M., Kostanjevečki, V., Grognet, P., Vanmechelen, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.004 · Cited by 86 · see citing works

High-Level Expression of the Mnb/Dyrk1A Gene in Brain and Heart during Rat Early Development

Okui, M., Ide, T., Morita, K., Funakoshi, E., Ito, F., Ogita, K., Yoneda, Y., Kudoh, J., & Shimizu, N. (1999) · Genomics · doi:10.1006/geno.1999.5998 · Cited by 86 · see citing works

Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1

Park, J., Oh, Y., & Chung, K. C. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.1.006 · Cited by 86 · see citing works

Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome

Siarey, R. J., Kline‐Burgess, A., Cho, M., Balbo, A., Best, T. K., Harashima, C., Klann, E., & Galdzicki, Z. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03971.x · Cited by 86 · see citing works

DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1

Kelly, P. A., & Rahmani, Z. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1085 · Cited by 86 · cited 4× · see citing works

Altered longevity‐assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death

Pehar, M., O’Riordan, K. J., Burns‐Cusato, M., Andrzejewski, M. E., del Alcazar, C. R. G., Bürger, C., Scrable, H. J., & Puglielli, L. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00547.x · Cited by 85 · see citing works

The spatio‐temporal and subcellular expression of the candidate Down syndrome gene <i>Mnb/Dyrk1A</i> in the developing mouse brain suggests distinct sequential roles in neuronal development

Hämmerle, B., Elizalde, C., & Tejedor, F. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06092.x · Cited by 82 · see citing works

Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A

Fernandez-Martinez, J., Vela, E. M., Tora-Ponsioen, M., Ocaña, O. H., Nieto, M., & Galceran, J. (2009) · Journal of Cell Science · doi:10.1242/jcs.044354 · Cited by 81 · see citing works

Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain

Węgiel, J., Kuchna, I., Nowicki, K., Frackowiak, J., Dowjat, K., Silverman, W. P., Reisberg, ‌., de Leon, M. J., Wısnıewskı, T., Adayev, T., et al. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.008 · Cited by 80 · see citing works

Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome

Hunter, C. L., Ole Isacson, A., Nelson, M., Bimonte‐Nelson, H. A., Seo, H., Lin, L., Ford, K. A., Kindy, M. S., & Granholm, A. (2003) · Neuroscience Research · doi:10.1016/s0168-0102(03)00005-1 · Cited by 80 · see citing works

The down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4

Sitz, J. H., Baumgärtel, K., Hämmerle, B., Papadopoulos, C., Hekerman, P., Tejedor, F. J., Becker, W. B., & Lutz, B. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.034 · Cited by 79 · see citing works

Regulation of Caspase 9 through Phosphorylation by Protein Kinase C Zeta in Response to Hyperosmotic Stress

Brady, S. C., Allan, L. A., & Clarke, P. R. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10543-10555.2005 · Cited by 79 · see citing works

Behavioral and neurobiological markers of Alzheimer’s disease in Ts65Dn mice: effects of estrogen

Hunter, C. L., Bimonte‐Nelson, H. A., Nelson, M., Eckman, C. B., & Granholm, A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.10.010 · Cited by 77 · see citing works

Activity-dependent facilitation of Synaptojanin and synaptic vesicle recycling by the Minibrain kinase

Chen, C., Brégère, C., Paluch, J., Lu, J. F., Dickman, D. K., & Chang, K. T. (2014) · Nature Communications · doi:10.1038/ncomms5246 · Cited by 77 · see citing works

Sprouty2-Mediated Inhibition of Fibroblast Growth Factor Signaling Is Modulated by the Protein Kinase DYRK1A

Aranda, S., Álvarez, M., Turró, S., Laguna, A., & de la Luna, S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00394-08 · Cited by 76 · see citing works

Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome

Stagni, F., Giacomini, A., Emili, M., Trazzi, S., Guidi, S., Sassi, M., Ciani, E., Rimondini, R., & Bartesaghi, R. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.07.031 · Cited by 76 · see citing works

Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development

Dang, T., Duan, W. Y., Yu, B., Tong, D. L., Cheng, C., Zhang, Y. F., Wu, W., Ye, K., Zhang, W. X., Wu, M., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.253 · Cited by 76 · see citing works

Mechanism of dual specificity kinase activity of DYRK 1 A

Walte, A., Rüben, K., Birner‐Gruenberger, R., Preisinger, C., Bamberg‐Lemper, S., Hilz, N., Bracher, F., & Becker, W. B. (2013) · FEBS Journal · doi:10.1111/febs.12411 · Cited by 75 · see citing works

Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of down syndrome

Altafaj, X., Martín, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrín, C., Dierssen, M., & Fillat, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.017 · Cited by 75 · see citing works

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice

Naert, G., Ferré, V. M., Meunier, J., Keller, E., Malmström, S., Givalois, L., Carreaux, F., Bazureau, J. P., & Maurice, T. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.018 · Cited by 75 · see citing works

Development of DANDYs, New 3,5-Diaryl-7-azaindoles Demonstrating Potent DYRK1A Kinase Inhibitory Activity

Gourdain, S., Dairou, J., Denhez, C., Bui, L. C., Rodrigues‐Lima, F., Janel, N., Delabar, J. M., Cariou, K., & Dodd, R. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401049v · Cited by 74 · see citing works

Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone Homeostasis

Lee, Y., Ha, J., Kim, H. J., Kim, Y.-S., Chang, E., Song, W., & Kim, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042234 · Cited by 73 · see citing works

Phosphorylation and Inactivation of Glycogen Synthase Kinase 3β (GSK3β) by Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A)

Song, W., Song, E. C., Jung, M., Choi, S., Baik, H.-H., Jin, B. K., Kim, J. H., & Chung, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.594952 · Cited by 72 · see citing works

Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I

Jin, N., Yin, X., Gu, J., Zhang, X., Shi, J., Qian, W., Ji, Y., Cao, M., Gu, X., Ding, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645507 · Cited by 71 · see citing works

Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice

Nakano-Kobayashi, A., Awaya, T., Kii, I., Sumida, Y., Okuno, Y., Yoshida, S., Sumida, T., Inoue, H., Hosoya, T., & Hagiwara, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704143114 · Cited by 71 · see citing works

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives

Neumann, F., Gourdain, S., Albac, C., Dekker, A. D., Bui, L. C., Dairou, J., Schmitz-Afonso, I., Hue, N., Rodrigues-Lima, F., Delabar, J. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20984-z · Cited by 71 · see citing works

Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome

Ortiz-Abalia, J., Sahún, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M., & Fillat, C. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.09.010 · Cited by 70 · see citing works

Phosphorylation of Amphiphysin I by Minibrain Kinase/Dual-specificity Tyrosine Phosphorylation-regulated Kinase, a Kinase Implicated in Down Syndrome

Murakami, N., Xie, W. Q., Lu, R. C., Chen‐Hwang, M., Wieraszko, A., & Hwang, Y. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513497200 · Cited by 70 · see citing works

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors

Rüben, K., Wurzlbauer, A., Walte, A., Sippl, W., Bracher, F., & Becker, W. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132453 · Cited by 65 · see citing works

Dyrk1A Potentiates Steroid Hormone-Induced Transcription via the Chromatin Remodeling Factor Arip4

Sitz, J. H., Tigges, M., Baumgärtel, K., Хаспеков, Л. Г., & Lutz, B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5821-5834.2004 · Cited by 64 · see citing works

GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome

Martín, J. Z. D. S., Delabar, J. M., Bacci, A., & Potier, M. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.002 · Cited by 64 · see citing works

Age-Related Neurodegeneration and Memory Loss in Down Syndrome

Lockrow, J. P., Fortress, A. M., & Granholm, A. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/463909 · Cited by 64 · see citing works

New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome

Park, J., & Chung, K. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.4.244 · Cited by 63 · see citing works

Sex Differences in the Cholinergic Basal Forebrain in the Ts65Dn Mouse Model of D own Syndrome and A lzheimer's Disease

Kelley, C. M., Powers, B. E., Velázquez, R., Ash, J. A., Ginsberg, S. D., Strupp, B. J., & Mufson, E. J. (2013) · Brain Pathology · doi:10.1111/bpa.12073 · Cited by 62 · see citing works

The Place of Choline Acetyltransferase Activity Measurement in the “Cholinergic Hypothesis” of Neurodegenerative Diseases

Contestabile, A., Ciani, E., & Contestabile, A. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9497-4 · Cited by 62 · see citing works

Parallel RNAi screens across different cell lines identify generic and cell type-specific regulators of actin organization and cell morphology

Liu, T., Sims, D., & Baum, B. (2009) · Genome biology · doi:10.1186/gb-2009-10-3-r26 · Cited by 62 · see citing works

Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of down syndrome

Park, J., Yang, E. J., Yoon, J. H., & Chung, K. C. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.07.007 · Cited by 61 · see citing works

DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation

Miyata, Y., & Nishida, E. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.023 · Cited by 60 · see citing works

Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A

Ding, S., Shi, J., Qian, W., Iqbal, K., Grundke, I., Gong, C., & Liu, F. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.021 · Cited by 60 · see citing works

Influence of prenatal EGCG treatment andDyrk1adosage reduction on craniofacial features associated with Down syndrome

McElyea, S. D., Starbuck, J. M., Tumbleson, D. M., Harrington, E., Blazek, J. D., Ghoneima, A. A. M., Kula, K. S., & Roper, R. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw309 · Cited by 59 · see citing works

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes

Stringer, M., Abeysekera, I., Thomas, J. R., LaCombe, J., Stancombe, K., Stewart, R. B., Dria, K. J., Wallace, J. M., Goodlett, C. R., & Roper, R. J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.05.003 · Cited by 59 · see citing works

MNB/DYRK1A phosphorylation regulates the interactions of synaptojanin 1 with endocytic accessory proteins

Adayev, T., Chen‐Hwang, M., Murakami, N., Wang, R., & Hwang, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.169 · Cited by 57 · see citing works

Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors

Anderson, K., Chen, Y., Chen, Z., Dominique, R., Glenn, K., He, Y., Janson, C. A., Luk, K., Lukacs, C., Polonskaia, A., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.10.055 · Cited by 57 · see citing works

Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a

Maréchal, D., Brault, V., Léon, A., Martin, D., Pereira, P. L., Loaëc, N., Birling, M., Friocourt, G., Blondel, M., & Hérault, Y. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy447 · Cited by 56 · see citing works

Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice

Souchet, B., Audrain, M., Billard, J. M., Dairou, J., Fol, R. R., Orefice, N. S., Tada, S., Gu, Y., Dufayet‐Chaffaud, G., Limanton, E., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0678-6 · Cited by 55 · see citing works

P44, the ‘longevity‐assurance’ isoform of P53, regulates tau phosphorylation and is activated in an age‐dependent fashion

Pehar, M., Ko, M. H., Li, M., Scrable, H. J., & Puglielli, L. (2013) · Aging Cell · doi:10.1111/acel.12192 · Cited by 54 · see citing works

A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons

Vidaki, M., Drees, F., Saxena, T., Lanslots, E., Taliaferro, J. M., Tatarakis, A., Burge, C. B., Wang, E. T., & Gertler, F. B. (2017) · Neuron · doi:10.1016/j.neuron.2017.06.048 · Cited by 54 · see citing works

Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models

Souchet, B., Duchon, A., Gu, Y., Dairou, J., Chevalier, C., Daubigney, F., Nalesso, V., Créau, N., Yu, Y., Janel, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40328-9 · Cited by 54 · see citing works

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair

Guard, S., Poss, Z., Ebmeier, C., Pagratis, M., Simpson, H., Taatjes, D., & Old, W. (2018) · Scientific Reports · doi:10.1038/s41598-019-42990-5 · Cited by 54 · see citing works

Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade

Chiu, C., Yeh, T., Chen, R., Chen, H., Huang, Y., Weng, Y.-H., Cheng, Y., Liu, Y.-C., Cheng, A., Lu, Y.-C., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00399 · Cited by 54 · see citing works

Chronic Treatment with a Promnesiant GABA-A -Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model

Braudeau, J., Dauphinot, L., Duchon, A., Loistron, A., Dodd, R. H., Hérault, Y., Delatour, B., & Potier, M. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/153218 · Cited by 53 · see citing works

DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169

Menon, V., Ananthapadmanabhan, V., Swanson, S. K., Saini, S., Sesay, F. F., Yakovlev, V. A., Florens, L. A., DeCaprio, J. A., Washburn, M. P., Dozmorov, M. G., et al. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1577525 · Cited by 53 · see citing works

Mnb/Dyrk1A Phosphorylation Regulates the Interaction of Dynamin 1 with SH3 Domain-Containing Proteins

Huang, Y. Q., Chen‐Hwang, M., Dolios, G., Murakami, N., Padovan, J. C., Wang, R., & Hwang, Y. (2004) · Biochemistry · doi:10.1021/bi036060+ · Cited by 51 · see citing works

p38α- and DYRK1A-dependent phosphorylation of caspase-9 at an inhibitory site in response to hyperosmotic stress

Seifert, A., & Clarke, P. R. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.06.009 · Cited by 50 · see citing works

Characterization of a Domain That Transiently Converts Class 2 DYRKs into Intramolecular Tyrosine Kinases

Kinstrie, R., Luebbering, N., Miranda‐Saavedra, D., Sibbet, G. J., Han, J., Lochhead, P. A., & Cleghon, V. (2010) · Science Signaling · doi:10.1126/scisignal.2000579 · Cited by 50 · see citing works

Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules

Rothweiler, U., Stensen, W., Brandsdal, B. O., Isaksson, J. M., Leeson, F., Engh, R. A., & Svendsen, J. S. M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01086 · Cited by 50 · see citing works

A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down Syndrome Mouse Model

Lockrow, J. P., Boger, H. A., Gerhardt, G. A., Aston‐Jones, G., Bachman, D., & Granholm, A. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101218 · Cited by 49 · see citing works

A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response

Roewenstrunk, J., Vona, C. D., Chen, J., Borràs, E., Dong, C., Arató, K., Sabidó, E., Huen, M. S. Y., & de la Luna, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-42445-x · Cited by 48 · see citing works

Alterations to Dendritic Spine Morphology, but Not Dendrite Patterning, of Cortical Projection Neurons in Tc1 and Ts1Rhr Mouse Models of Down Syndrome

Haas, M. A., Bell, D., Slender, A., Lana-Elola, E., Watson-Scales, S., Fisher, E. M. C., Tybulewicz, V. L. J., & Guillemot, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078561 · Cited by 48 · see citing works

The Molecular Chaperone TRiC/CCT Binds to the Trp-Asp 40 (WD40) Repeat Protein WDR68 and Promotes Its Folding, Protein Kinase DYRK1A Binding, and Nuclear Accumulation

Miyata, Y., Shibata, T., Aoshima, M., Tsubata, T., & Nishida, E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586115 · Cited by 47 · see citing works

DYRK1A phoshorylates histone H3 to differentially regulate the binding of HP1 isoforms and antagonize HP1‐mediated transcriptional repression

Jang, S. M., Azébi, S., Soubigou, G., & Muchardt, C. (2014) · EMBO Reports · doi:10.15252/embr.201338356 · Cited by 47 · see citing works

DYRK1A-mediated phosphorylation of GluN2A at Ser1048 regulates the surface expression and channel activity of GluN1/GluN2A receptors

Grau, C. J. A., Arató, K., Fernández‐Fernández, J. M., Valderrama, A., Sindreu, C. B., Fillat, C., Ferrer, I., de la Luna, S., & Altafaj, X. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00331 · Cited by 46 · see citing works

Dyrk1A Binds to Multiple Endocytic Proteins Required for Formation of Clathrin-Coated Vesicles

Murakami, N., Bolton, D., & Hwang, Y. (2009) · Biochemistry · doi:10.1021/bi9010557 · Cited by 45 · see citing works

Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells

Kang, J. E., Choi, S. A., Park, J. B., & Chung, K. C. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20534 · Cited by 45 · see citing works

Expression of the Mnb (dyrk) Protein in Adult and Embryonic Mouse Tissues

Rahmani, Z., Lopes, C., Rachidi, M., & Delabar, J. M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9803 · Cited by 44 · see citing works

Dyrk1A negatively regulates the actin cytoskeleton through threonine phosphorylation of N-WASP

Park, J., Sung, J. Y., Park, J., Song, W., Chang, S., & Chung, K. C. (2012) · Journal of Cell Science · doi:10.1242/jcs.086124 · Cited by 44 · see citing works

Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult down syndrome mice

Goodlett, C. R., Stringer, M., LaCombe, J., Patel, R., Wallace, J. M., & Roper, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67133-z · Cited by 43 · see citing works

Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ

Sonamoto, R., Kii, I., Koike, Y., Sumida, Y., Kato‐Sumida, T., Okuno, Y., Hosoya, T., & Hagiwara, M. (2015) · Scientific Reports · doi:10.1038/srep12728 · Cited by 42 · see citing works

Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down's syndrome

Andrade‐Talavera, Y., Benito, I., Casañas, J. J., Moreno, A. R., & Montesinos, M. L. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.005 · Cited by 42 · see citing works

Neurodevelopmental disorder risk gene DYRK1A is required for ciliogenesis and brain size in Xenopus embryos

Willsey, H. R., Xu, Y., Everitt, A., Dea, J., Exner, C. R. T., Willsey, A. J., State, M. W., & Harland, R. M. (2020) · Development · doi:10.1242/dev.189290 · Cited by 42 · see citing works

Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors

Drung, B., Scholz, C., Barbosa, V. A., Nazari, A., Sarragiotto, M. H., & Schmidt, B. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.054 · Cited by 41 · see citing works

Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome

Brault, V., Nguyen, T. L., Gutiérrez, J. F., Iacono, G. L., Birling, M., Lalanne, V., Méziane, H., Manousopoulou, A., Pavlovic, G., Lindner, L., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009777 · Cited by 41 · see citing works

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

Arranz, J., Balducci, E., Arató, K., Sánchez‐Elexpuru, G., Najas, S., Parras, A., Rebollo, E., Pijuan, I., Erb, I., Verde, G., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.022 · Cited by 40 · see citing works

REST Regulates DYRK1A Transcription in a Negative Feedback Loop

Lü, M., Zheng, L., Han, B., Wang, L., Wang, P., Liu, H., & Sun, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174540 · Cited by 39 · see citing works

The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A–PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine

Alexeeva, M., Åberg, E., Engh, R. A., & Rothweiler, U. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715005106 · Cited by 38 · see citing works

Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice

Mazur‐Kolecka, B., Golabek, A. A., Kida, E., Rabe, A., Hwang, Y., Adayev, T., Węgiel, J., Flory, M. J., Kaczmarski, W., Marchi, E. J., et al. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23007 · Cited by 38 · see citing works

Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome

Altafaj, X., Ortiz-Abalia, J., Fernández, M., Potier, M., Laffaire, J., Andreu, N., Dierssen, M., González-García, C., Ceña, V., Martı́, E., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.07.024 · Cited by 38 · see citing works

Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome

Starbuck, J. M., Llambrich, S., González, R., Albaigès, J., Sarlé, A., Wouters, J., González, A., Sevillano, X., Sharpe, J. A., de la Torre, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83757-1 · Cited by 38 · see citing works

Multi-influential genetic interactions alter behaviour and cognition through six main biological cascades in Down syndrome mouse models

Duchon, A., Moreno, M. D. M. M., Lorenzo, S. M., de Souza, M. P. S., Chevalier, C., Nalesso, V., Méziane, H., de Sousa, P. L., Noblet, V., Armspach, J., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab012 · Cited by 38 · see citing works

Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Does Not Require Tyrosine Phosphorylation for Activity in Vitro

Adayev, T., Chen‐Hwang, M., Murakami, N., Lee, E., Bolton, D. C., & Hwang, Y. (2007) · Biochemistry · doi:10.1021/bi700251n · Cited by 38 · see citing works

Identification of a DYRK1A-mediated phosphorylation site within the nuclear localization sequence of the hedgehog transcription factor GLI1

Ehe, B. K., Lamson, D. R., Tarpley, M., Onyenwoke, R. U., Graves, L. M., & Williams, K. P. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.107 · Cited by 38 · see citing works

Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate

Lindberg, M. F., Deau, E., Miege, F., Greverie, M., Roche, D., George, N. S., George, P. G., Merlet, L., Gavard, J., Brugman, S. J. T., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01888 · Cited by 55 · see citing works

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases

Lindberg, M. F., Deau, E., Arfwedson, J., George, N. S., George, P. G., Alfonso, P., Corrionero, A., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02068 · Cited by 52 · see citing works

Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B

Deau, E., Lindberg, M. F., Miege, F., Roche, D., George, N. S., George, P. G., Krämer, A., Knapp, S., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00884 · Cited by 42 · see citing works

The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives

Stagni, F., & Bartesaghi, R. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.903729 · Cited by 31 · see citing works

Dose imbalance of DYRK1A kinase causes systemic progeroid status in Down syndrome by increasing the un-repaired DNA damage and reducing LaminB1 levels

Murray, A., Gough, G., Cindrić, A., Vučković, F., Koschut, D., Borelli, V., Petrović, D. J., Bekavac, A., Plećaš, A., Hribljan, V., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104692 · Cited by 37 · see citing works

DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner

Strine, M. S., Cai, W. L., Wei, J., Alfajaro, M. M., Filler, R. B., Biering, S. B., Sarnik, S. A., Chow, R. D.-W., Patil, A., Cervantes, K. S., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002097 · Cited by 29 · see citing works

Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome

Meijer, L., Chrétien, E., & Ravel, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240078 · Cited by 30 · see citing works

Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions

Murphy, A. J., Wilton, S. D., Aung-Htut, M. T., & McIntosh, C. S. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1391564 · Cited by 27 · see citing works

Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care

Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 26 · see citing works

Screening of a Halogen-Enriched Fragment Library Leads to Unconventional Binding Modes

Dammann, M., Stahlecker, J., Zimmermann, M. O., Klett, T., Rotzinger, K., Krämer, M., Coles, M. P., Stehle, T., & Boeckler, F. M. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00951 · Cited by 26 · see citing works

Intranasal Administration of KYCCSRK Peptide Rescues Brain Insulin Signaling Activation and Reduces Alzheimer’s Disease-like Neuropathology in a Mouse Model for Down Syndrome

Tramutola, A., Lanzillotta, S., Aceto, G., Pagnotta, S. E., Ruffolo, G., Cifelli, P., Marini, F., Ripoli, C., Palma, E., Grassi, C., et al. (2023) · Antioxidants · doi:10.3390/antiox12010111 · Cited by 25 · see citing works

Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A

Ananthapadmanabhan, V., Shows, K. H., DICKINSON, A. J. G., & Litovchick, L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1277537 · Cited by 23 · see citing works

State-of-the-art therapy for down syndrome

Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine &amp; Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22 · see citing works

Understanding the genetic mechanisms and cognitive impairments in Down syndrome: towards a holistic approach

Abukhaled, Y., Hatab, K., Awadhalla, M., & Hamdan, H. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11890-0 · Cited by 21 · see citing works

An inhibitory circuit-based enhancer of DYRK1A function reverses Dyrk1a-associated impairment in social recognition

Shih, Y., Alipio, J. B., & Sahay, A. (2023) · Neuron · doi:10.1016/j.neuron.2023.09.009 · Cited by 22 · see citing works

RUN(X) out of blood: emerging RUNX1 functions beyond hematopoiesis and links to Down syndrome

Rozen, E. J., Ozeroff, C. D., & Allen, M. A. (2023) · Human Genomics · doi:10.1186/s40246-023-00531-2 · Cited by 17 · see citing works

Overexpression screen of chromosome 21 genes reveals modulators of Sonic hedgehog signaling relevant to Down syndrome

Moyer, A. J., Fernandez, F., Li, Y., Klinedinst, D. K., Florea, L., Kazuki, Y., Oshimura, M., & Reeves, R. H. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049712 · Cited by 17 · see citing works

Identification of FAM53C as a cytosolic-anchoring inhibitory binding protein of the kinase DYRK1A

Miyata, Y., & Nishida, E. (2023) · Life Science Alliance · doi:10.26508/lsa.202302129 · Cited by 17 · see citing works

Dyrk1a Phosphorylation of α-Synuclein Mediating Apoptosis of Dopaminergic Neurons in Parkinson’s Disease

Yong, Y., Wu, Q., Meng, X., Lu, R., Xia, H., Pei, F., & Yang, X. (2023) · Parkinson s Disease · doi:10.1155/2023/8848642 · Cited by 14 · see citing works

Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome

Noll, C., Kandiah, J., Moroy, G., Gu, Y., Dairou, J., & Janel, N. (2022) · Nutrients · doi:10.3390/nu14102039 · Cited by 14 · see citing works

Chr21 protein–protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer’s disease

Viard, J., Loe-Mie, Y., Daudin, R., Khelfaoui, M., Plançon, C., Boland, A., Tejedor, F. J., Huganir, R. L., Kim, E., Kinoshita, M., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101205 · Cited by 11 · see citing works

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation

Tu, H., Chao, M., Lee, C., Peng, C.-S., Wu, Y., Lin, T. E., Chang, Y.-W., Yen, S., Hsu, K., Pan, S., et al. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2418470 · Cited by 11 · see citing works

CRISPR/Cas9-Induced Inactivation of the Autism-Risk Gene setd5 Leads to Social Impairments in Zebrafish

Gabellini, C., Pucci, C., Cesari, C. D., Martini, D., Lauro, C. D., Digregorio, M., Norton, W., Zippo, A., Sessa, A., Broccoli, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010167 · Cited by 11 · see citing works

The response to single-gene duplication implicates translation as a key vulnerability in aneuploid yeast

Dutcher, H. A., Hose, J., Howe, H., Rojas, J., & Gasch, A. P. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011454 · Cited by 11 · see citing works

Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model

Hawley, L. E., Stringer, M., Deal, A. J., Folz, A., Goodlett, C. R., & Roper, R. J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106359 · Cited by 10 · see citing works

Dyrk1a is required for craniofacial development in Xenopus laevis.

Johnson, H. K., Wahl, S., Sesay, F. F., Litovchick, L., & DICKINSON, A. J. G. (2024) · Developmental Biology · doi:10.1016/j.ydbio.2024.04.004 · Cited by 10 · see citing works

Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model

LaCombe, J., Sloan, K., Thomas, J. R., Blackwell, M. P., Crawford, I., Bishop, F., Wallace, J. M., & Roper, R. J. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050914 · Cited by 9 · see citing works

Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor

Paclibar, C. G., Schafer, D. M., Biju, A. P., Karim, F., Sison, S. A., Liang, C., Ahmed, S. T., & Mukherjee, J. (2025) · Molecules · doi:10.3390/molecules30050990 · Cited by 7 · see citing works

Neurodevelopment in congenital heart disease: a review of antenatal mechanisms and therapeutic potentials

Sajid, A., Chavez‐Valdez, R., Sharp, A. N., & Shah, D. K. (2025) · Pediatric Research · doi:10.1038/s41390-025-04360-y · Cited by 8 · see citing works

DYRK1A in the physiology and pathology of the neuron-astrocyte axis

Cisternas, P., Kim, J.-Y., Ashfeld, B. L., & Zartman, J. J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1626062 · Cited by 7 · see citing works

Unlocking the Therapeutic Potential of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitors in Alzheimer’s Diseases

Karati, D., Meur, S., Saha, A., Saha, T., & Sen, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04806-8 · Cited by 6 · see citing works

The fetal brain neurosonography in trisomy 21: the seagull sign and thinned subplate

Pooh, R. K., Machida, M., Uenishi, K., Barreto, E. Q., Wah, Y. M. I., Poon, L. C., Itoh, K., Nakamura, T. K., Chiyo, H., Ohashi, H., et al. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.04.054 · Cited by 5 · see citing works

DYRK1A in blood and immune function: implications in leukemia, inflammatory disorders, infection and Down syndrome

Rozen, E. J., Dowell, R. D., & Allen, M. A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1587089 · Cited by 6 · see citing works

Ripply3 overdosage induces mid-face shortening through Tbx1 downregulation in Down syndrome models

Saavedra, J. T. A., Chevalier, C., Bloch‐Zupan, A., & Hérault, Y. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011873 · Cited by 8 · see citing works

Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD

Lee, H., Kang, S., Lee, Y. J., Oh, S., Joo, B., Hwang, J.-W., Kim, J., Kim, T.-E., Jung, T.-M., Kim, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1661791 · Cited by 6 · see citing works

The role of Goldilocks protein kinase DYRK1A in embryonic development

Johnson, H. K., Litovchick, L., & DICKINSON, A. J. G. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2025.06.009 · Cited by 5 · see citing works

Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review

Jacob, C., Tollenaere, M., Kachar, H., Potier, M., Deyn, P. P. D., & Dam, D. V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41445 · Cited by 5 · see citing works

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2024) · eLife · doi:10.7554/elife.89763.3 · Cited by 5 · see citing works

The RAS-Regulated RAF-MEK1/2-ERK1/2 Protein Kinase Pathway: The Path Most Traveled in RASopathies

Dutkiewicz, R., Sharpe, H. J., & Cook, S. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_18 · Cited by 5 · see citing works

The PTCHD1 protein: A prominent actor in brain function and in neurodevelopmental disorders

Ung, D. C., Martin, S., Hérault, Y., & Laumonnier, F. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106307 · Cited by 4 · see citing works

Multimodal quantitative MRI reveals age-related biophysical alterations in the human brain across the adult lifespan

Chen, X., Yuan, Z., Zhang, J., & Zhang, X.-Y. (2026) · NeuroImage · doi:10.1016/j.neuroimage.2026.121742 · Cited by 4 · see citing works

Early Chronic Fluoxetine Treatment of Ts65Dn Mice Rescues Synaptic Vesicular Deficits and Prevents Aberrant Proteomic Alterations

Fatemi, S. H., Otte, E. D., Folsom, T. D., Eschenlauer, A. C., Roper, R. J., Aman, J. W., & THURAS, P. D. (2024) · Genes · doi:10.3390/genes15040452 · Cited by 4 · see citing works

Sex specific emergence of trisomic Dyrk1a -related skeletal phenotypes in the development of a Down syndrome mouse modelPreprint

LaCombe, J., Sloan, K., Thomas, J. R., Blackwell, M. P., Crawford, I., Wallace, J. M., & Roper, R. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.24.595804 · Cited by 4 · see citing works

Structural Dynamics and Network Pharmacology for the Discovery of Inhibitors Targeting DYRK1 A in Neurological Disorders

Alam, P., Arshad, M. F., & Sharma, P. K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04935-0 · Cited by 3 · see citing works

Vertebrate and Invertebrate Animal Models for the Study of Down Syndrome

Granholm, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168092 · Cited by 3 · see citing works

Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells

West, N. R., Lindberg, M. F., Dairou, J., MacGregor, S., Puthireddy, S., Meijer, L., & Bhattacharyya, A. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052740 · Cited by 3 · see citing works

Interneuron migration defects during corticogenesis contribute to Dyrk1a haploinsufficiency syndrome pathogenesis

Hinckelmann, M.-V., Dubos, A., Artot, V., Rudolf, G., Nguyen, T. L., Tilly, P., Nalesso, V., Moreno, M. D. M. M., Birling, M., Godin, J. D., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03109-7 · Cited by 4 · see citing works

DYRK1A and Parkinson’s disease, facts and hypotheses

Meijer, L., Lindberg, M. F., Hogrel, G., & Khor, B. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107379 · Cited by 2 · see citing works

ROCK2 Knockout Improves Proliferation Rate in a Cellular Model of Down SyndromePreprint

LeBlanc-Straceski, J., Williams, R., Ward, K., Bates, A., Duran, C., Anderson, L., Murray, M., Pereira-Badji, J., Shoushani, C., & Thibault, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.20.513071 · Cited by 2 · see citing works

Interneuron migration defects during corticogenesis contribute to Dyrk1a haploinsufficiency syndrome pathogenesis via actomyosin dynamics deregulationsPreprint

Hinckelmann, M.-V., Dubos, A., Artot, V., Rudolf, G., Nguyen, T. L., Tilly, P., Nalesso, V., Moreno, M. D. M. M., Birling, M., Godin, J. D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.09.566424 · Cited by 2 · see citing works

Myocardial DYRK1B Expression Is Increased in Patients with Impaired Cardiac Contractility and Sleep-Disordered Breathing

Bayram, F., Hegner, P., Lauerer, A.-M., Schildt, S., Wermers, D., Baier, M. J., Mustroph, J., Tafelmeier, M., Provazník, Z., Schmid, C., et al. (2025) · Antioxidants · doi:10.3390/antiox14020163 · Cited by 1 · see citing works

Chromosome duplication causes premature aging via defects in ribosome quality control

Escalante, L. E., Hose, J., Ahrens, J. M., Howe, H., Paulsen, N., Liss, S. J., Place, M., & Gasch, A. P. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003509 · Cited by 1 · see citing works

Epigenetic treatment of synaptic and behavioral deficits in Dyrk1a-mutant mice

Lin, C.-H., Yu, M., Patel, P. J., Li, P., & Yan, Z. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02353-x · Cited by 1 · see citing works

miRNAs mediated Hsa21 gene suppression as potential therapeutic agent for Down syndrome: molecular dynamics and MM/PBSA-based study

Sinha, P., & Yadav, A. K. (2026) · Journal of Molecular Modeling · doi:10.1007/s00894-026-06634-6 · Cited by 1 · see citing works

Targeting dual specificity tyrosine-phosphorylation-regulated kinase 1A mitigates tauopathy and enhances recovery after repetitive head injury

Melchior, B., Browning, M., McCartan, R., Lai, C., Hahn-Townsend, C., Gratkowski, A., Morin, A., MULLAN, M. J., Crawford, F., Grifman, M., et al. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00843 · Cited by 1 · see citing works

Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome

Nambara, T., Lee, J. Y., Minami, M., Okamoto, S., Kawatani, K., Kusakabe, H., Yoshimatsu, H., Hirata, K., Yoshimi, K., Mashimo, T., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09902-6 · Cited by 1 · see citing works

Mapping the Brain Interaction Network of the Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Targeted by Leucettinib-21 Using Affinity Chromatography

Deau, E., Simon, C., Hogrel, G., CAILLETTE, J., Dairou, J., Hérault, Y., Morlet, B., Miyata, Y., Meijer, L., & Lindberg, M. F. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00066 · Cited by 1 · see citing works

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2023) · eLife · doi:10.1101/2023.07.31.551282 · Cited by 6 · see citing works

Ripply3 overdosage induces mid-face shortening through Tbx1 downregulation in Down syndrome modelsPreprint

Saavedra, J. T. A., Chevalier, C., Bloch‐Zupan, A., & Hérault, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.13.612914 · Cited by 1 · see citing works

Kinase-independent activity of DYRK1A promotes viral entry of highly pathogenic human coronavirusesPreprint

Strine, M. S., Cai, W. L., Wei, J., Alfajaro, M. M., Filler, R., Biering, S. B., Sarnik, S. A., Patil, A., Cervantes, K. S., Collings, C. K., et al. (2022) · bioRxiv · doi:10.1101/2022.09.13.507833

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse modelPreprint

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2023) · eLife · doi:10.7554/elife.89763.1

Dyrk1a is Required for Craniofacial Development in Xenopus LaevisPreprint

DICKINSON, A. J. G., Johnson, H. K., Wahl, S. E., Sesay, F. F., & Litovchick, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4669820

Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse modelPreprint

Llambrich, S., Tielemans, B., Saliën, E., Atzori, M., Wouters, K., Bulck, V. V., Platt, M., Vanherp, L., Fernandez, N. G., de la Fuente, L. G., et al. (2024) · eLife · doi:10.7554/elife.89763.2

Using Drosophila to Study the Mechanisms That Underlie Down Syndrome

Ye, B. (2025) · Springer eBooks · doi:10.1007/978-3-031-78611-2_5

DYRK1A Overexpression Drives Muscle Wasting by Impeding Myogenesis via a USP7 ‐Axin1‐β‐Catenin Regulatory Axis in Mice

Lü, M., Li, X., Ma, L., Wang, X., Ma, J., Zhao, J., & Lu, Q. (2025) · IUBMB Life · doi:10.1002/iub.70061

Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 iPSC-derived neural cellsPreprint

West, N. R., Lindberg, M. F., Dairou, J., MacGregor, S., Puthireddy, S., Meijer, L., & Bhattacharyya, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.05.704014

Editorial: Advances in DYRK1A syndrome: underlying mechanisms, disease models, and novel therapeutic approaches

Glass, O. K., Piton, A., & Pfalzer, A. C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1803346

The DYRK Family: A Key Regulator of Metabolic Homeostasis and Its Therapeutic Potential in Kidney Diseases

Zhu, Y., Qiao, P.-F., Gan, Y., Fu, X., Huang, X., Sun, S., Gou, Y.-F., Xia, W., Ma, F., & Liu, L. (2026) · MedComm – Future Medicine · doi:10.1002/mef2.70050

Craniofacial analysis of Down syndrome rodent models

Saavedra, J. T. A. (2024) · doi:10.70675/064b45abz323ez478ez93ddz8ce0747170c2

LONG-TERM NEURODEVELOPMENTAL AND COGNITIVE OUTCOMES FOLLOWING PRENATAL INHIBITION OF DYRK1A BY LEUCETTINE L41 IN MOUSE MODELS OF DOWN SYNDROMEPreprint

Duchon, A., Chevalier, C., Gizzi, P., Dairou, J., & Hérault, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724917

The Phosphoproteomic Landscape of CD2AP: A Comprehensive Review of Kinase Networks and Disease Implications

Sheela, A., Subair, S., Gopalakrishnan, A. P., Palollathil, A., & Raju, R. (2026) · OMICS A Journal of Integrative Biology · doi:10.1177/15578100261451308

Dual-specificity tyrosine phosphorylation-regulated kinase 1A in neurodegenerative disorders

Bagheri, S., & Saboury, A. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44173-8.00020-6

From Structure to Selectivity: Integrating CADD and AIDD in Rational Medicinal Chemistry Strategies for DYRK1A Inhibitor Discovery

Yu, M., Tang, S., Huang, L., Wang, Y., Xu, J., Zhu, H., & Yao, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00774

DYRK1A – a gene dose paradox

Plećaš, A., Gough, G., Kunštek, S., Babić, M., Murray, A., Nižetić, D., & Alić, I. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1963992

Evidence for functional convergence between LZTS2 and DYRK1A during craniofacial development

Cheng, N., Lima, S., Litovchick, L., & DICKINSON, A. J. G. (2026) · Developmental Dynamics · doi:10.1002/dvdy.70192

BindingDB Entry 50016019: Screening of a Halogen-Enriched Fragment Library Leads to Unconventional Binding Modes.

BindingDB (2023) · UC San Diego · doi:10.7270/q2rb78kg

BindingDB Entry 50020570: Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer's Disease Drug Candidate.

BindingDB (2024) · UC San Diego · doi:10.7270/q2mg7v01

BindingDB Entry 50018840: Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.

BindingDB (2024) · UC San Diego · doi:10.7270/q2x92gjt

BindingDB Entry 50020201: Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.

BindingDB (2024) · UC San Diego · doi:10.7270/q26m3c7h

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome

Féki, A., & Hibaoui, Y. (2018) · Brain Sciences · doi:10.3390/brainsci8100187 · Cited by 71 · see citing works

DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in down syndrome

Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181 · see citing works

Function and regulation of Dyrk1A: towards understanding Down syndrome

Park, J., Song, W., & Chung, K. C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0123-2 · Cited by 205 · see citing works

New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome

Park, J., & Chung, K. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.4.244 · Cited by 63 · see citing works

Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase‐1A (DYRK1A), A Master Regulatory Protein Involved in Down Syndrome Brain Alterations and Mental Disability, A Key Contributor to Neurodegenerative Disorders of Alzheimer's Disease and A Potential Therapeutic Target

Rachidi, M. (2022) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710023